SEARCH

SEARCH BY CITATION

References

  • 1
    Tannenbaum A , Olsson CA. Surgical pathology of benign prostatic hyperplasia. In Hinman F Jr , ed. Benign Prostatic Hypertrophy, Section II, Chap. 8. New York: Springer-Verlag, 1983: 6372.
  • 2
    Berry SJ , Coffey DS , Walsh PC , Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 4749.
  • 3
    Duncan BM , Garraway WM. Prostatic surgery for benign prostatic hyperplasia: meeting the expanding demand. Br J Urol 1993; 72: 7615.
  • 4
    Holtgrewe HL , Ackermann R , Bay-Nielsen H et al. Report from the Committee on the Economics of BPH. In Cockett ATK , Khoury S , Aso Y et al., eds, The 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International Ltd, 1996; 5170.
  • 5
    Kark SL , Gofin J , Abramson JH et al. Prevalence of selected health characteristics of men, a community health survey in Jerusalem. Israel J Med Sci 1979; 15: 73241.
  • 6
    Arrighi HM , Metter EJ , Guess HA , Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy, the Baltimore longitudinal study of aging. Urology 1991; Suppl. 35: 48.
  • 7
    Klause M-E , Jensen JB , Jorgensen PM , Niels EB-B. Some clinical aspects of uroflowmetry in elderly males. Scand J Urol Nephrol 1986; 20: 939.
  • 8
    Madsen PO , Iversen P. A point system for selecting operative candidates. In Hinman F Jr , ed, Benign Prostatic Hypertrophy. New York: Springer-Verlag, 1983; 7635.
  • 9
    Watanabe H , Saitoh M , Mishina T et al. Mass screening program for prostatic diseases with transrectal ultra-sonotomography. J Urol 1977; 17: 7468.
  • 10
    Garraway WM , Collins GN , Lee RJ. High prevalence of benign prostatic hypertrophyin the community. Lancet 1991; 338: 46971.
  • 11
    Chute CG , Panser LA , Girman CJ et al. The prevalence of prostatism: a population based survey of urinary symptoms. J Urol 1993; 150: 85.
  • 12
    Fowler FJ , Wennberg JE , Timothy RP. Symptom status and quality of life following prostatectomy. JAMA 1988; 259: 301822.
  • 13
    Abrams P. Symptom questionnaires in epidemiological studies of prostate disease. In Garraway M. ed, Epidemiology of Prostate Disease, Chap. 4. Berlin: Springer-Verlag, 1995: 3041.
  • 14
    Barry MJ , Fowler FJ Jr , O'Leary MP et al. Measurement Committee of the American Urological Association. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 1992; 148: 154957.
  • 15
    Bosch JLHR , Hop WCJ , Kirkels WI , Schroder FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol 1995; 75: 62230.
  • 16
    Girman CJ , Jacobsen SJ , Guess HA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 151015.
  • 17
    Guess HA , Chute CG , Garraway WM et al. Similar levels of urological symptoms have similar impact on Scottish and American men — although Scots report less symptoms. J Urol 1993; 150: 17015.
  • 18
    Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology 1994; 44: 1535.
  • 19
    Epstein RS , Deverka RA , Chute CG et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 143145.
  • 20
    Garraway WM , Russell EBAW , Lee RJ et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43: 31821.
  • 21
    Lee AT , Russell EBAW , Garraway WM , Prescott RJ. Three year follow-up of a community-based cohort of men with untreated benign prostatic hyperplasia. Eur Urol. 1996; 30: 1117.
  • 22
    Chai TC , Belville WD , McGuire EJ , Nyquist L. Specificity of the American Urological Association voiding symptom index: comparison of unselected and selected sample of both sexes. J Urol 1993; 150: 171013.
  • 23
    Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate 1989; Suppl. 2: 6977.
  • 24
    Boyle P , Fourcroy J , Garraway WM et al. Epidemiology and natural history of BPH. In Cockett ATK , Khoury S , Aso Y et al., eds, The 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International Ltd, 1996: 1950.
  • 25
    Alexander FE , Boyle P. The rise in prostate cancer; myth or reality? In Garraway WM , ed, Epidemiology of Prostate Disease. Berlin: Springer-Verlag, 1995: 192226.
  • 26
    Breslow N , Chan CW , Dhom G. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977; 20: 6808.
  • 27
    Mettlin C , Jones GW , Murphy GP. Trends in prostate care in the United States 1874–1990; observations from the patient care evaluation studies of the American College of Surgeons Commissions of Cancer. CA Cancer J Clin 1993; 48: 8391.
  • 28
    Tretli S , Engeland A , Haldorsen T et al. Prostate cancer — look to Denmark. Natl Canc Inst 1996; 88: 128.
  • 29
    Stanford JL , Wicklund KG , Blumenstein BA , Brawer MK. The changing epidemiology of prostate cancer in the Seattle-Puget Sound region 1974–1993. J Urol 1995; 153: 504A.
  • 30
    Lu-Yao GL , Greenberg R. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 2514.
  • 31
    Mettlin C , Jones GW , Averett H et al. Defining and updating the American Cancer Society guidelines for the cancer-related check-up: prostate and endometrial cancers. CA Cancer J Clin 1993; 43: 426.
  • 32
    Adami H-O , Baron JA , Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 95860.
  • 33
    Brendler CB. Characteristics of prostate cancers found with early detection regimes. Urology 1995; 46: 716.
  • 34
    Murphy WM , Dean PJ , Brasfield JA , Tatum L. Incidental carcinoma of the prostate. Am J Surg Pathol 1986; 10: 1704.
  • 35
    Gittes RF. Carcinoma of the prostate. N Eng J Med 1991; 4: 23645.
  • 36
    Labrie F , Bernand C , Leonello C et al. Diagnosis of advanced or non-curable prostate cancer can be practically eliminated by prostate specific antigen. Urology 1996; 47: 21216.
  • 37
    Pisani P , Parkin DM , Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891903.
  • 38
    Johansson J-E. Natural history in untreated prostate cancer. In Garraway WM , ed, Epidemiology of Prostate Disease. Berlin: Springer-Verlag, 1995: 22538.
  • 39
    Parkes C , Wald NJ , Murphy P et al. Prospective observational study to assess value of the prostate specific antigen as screening test for prostate cancer. Br Med J 1996; 312: 709.
  • 40
    World Population Reports. New York: United Nations, 1992.
  • 41
    Annual Abstract of Statistics. London: OPCS, 1994.
  • 42
    Jacobsen SJ , Girman CJ , Guess HA et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Arch Intern Med 1995; 155: 47781.